“Unlike radiation therapy that's got toxicity to it as it enters the body and exits the body and leaves large areas of necrotic tissue, histotripsy is very different in that there's generally no damage going in or going out.” HistoSonics’ CEO Mike Blue explains about the Edison system. He then in depth with BI analyst Matt Henriksson on how the Edison histotripsy technology destroys targeted cancer cells, how it differentiates from other cancer treatment options, and how the company plans to expand the use of Edison from lung cancer to kidney, pancreas and prostate indications. Also tune in to learn how the recent acquisition announcement can accelerate its momentum to build out the clinical data and commercialization of Edison.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.